circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p/SOCS3 axis
© 2023 John Wiley & Sons Ltd..
BACKGROUND: Non-small-cell lung cancer (NSCLC) is a common cancer. Chemotherapeutic drug resistance limits the therapeutic effect of NSCLC and leads to a poor prognosis. As a result, new specific targets may be better identified by studying the mechanism of drug resistance to cisplatin in NSCLC.
METHODS: In the present study, we performed a quantitative real-time polymerase chain reaction and western blotting to detect mRNA and protein levels. The proliferation of cells was analyzed by a Cell Counting Kit-8 and colony formation assays. Cell invasion was measured via the Transwell assay. A scratch assay was performed to measure cell migration in cisplatin (DDP)-resistant NSCLC cells. Apoptosis of cells was examined using flow cytometry.
RESULTS: We found that circANKRD28 was notably decreased in NSCLC. The results showed that circANKRD28 expression was not affected, and its half-life was more than 12 h. Functional experiments revealed that circANKRD28 overexpression inhibited DDP resistance in NSCLC cells in vitro. Mechanistic findings demonstrated that circANKRD28 regulated tumor cell progression and DDP sensitivity through the miR-221-3p/SOCS3 axis.
CONCLUSIONS: The present study revealed the regulatory effects and molecular mechanism of circANKRD28 on the development and cisplatin resistance in NSCLC, which may provide experimental basis and theoretical support to identify new targets for therapy of DDP resistance in NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
The journal of gene medicine - 25(2023), 4 vom: 05. Apr., Seite e3478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Song, Shu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.04.2023 Date Revised 16.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jgm.3478 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352507918 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352507918 | ||
| 003 | DE-627 | ||
| 005 | 20231226053901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jgm.3478 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352507918 | ||
| 035 | |a (NLM)36740786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Song, Shu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p/SOCS3 axis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2023 | ||
| 500 | |a Date Revised 16.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Non-small-cell lung cancer (NSCLC) is a common cancer. Chemotherapeutic drug resistance limits the therapeutic effect of NSCLC and leads to a poor prognosis. As a result, new specific targets may be better identified by studying the mechanism of drug resistance to cisplatin in NSCLC | ||
| 520 | |a METHODS: In the present study, we performed a quantitative real-time polymerase chain reaction and western blotting to detect mRNA and protein levels. The proliferation of cells was analyzed by a Cell Counting Kit-8 and colony formation assays. Cell invasion was measured via the Transwell assay. A scratch assay was performed to measure cell migration in cisplatin (DDP)-resistant NSCLC cells. Apoptosis of cells was examined using flow cytometry | ||
| 520 | |a RESULTS: We found that circANKRD28 was notably decreased in NSCLC. The results showed that circANKRD28 expression was not affected, and its half-life was more than 12 h. Functional experiments revealed that circANKRD28 overexpression inhibited DDP resistance in NSCLC cells in vitro. Mechanistic findings demonstrated that circANKRD28 regulated tumor cell progression and DDP sensitivity through the miR-221-3p/SOCS3 axis | ||
| 520 | |a CONCLUSIONS: The present study revealed the regulatory effects and molecular mechanism of circANKRD28 on the development and cisplatin resistance in NSCLC, which may provide experimental basis and theoretical support to identify new targets for therapy of DDP resistance in NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a circRNA | |
| 650 | 4 | |a mechanism | |
| 650 | 4 | |a microRNA | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a MIRN221 microRNA, human |2 NLM | |
| 650 | 7 | |a SOCS3 protein, human |2 NLM | |
| 650 | 7 | |a Suppressor of Cytokine Signaling 3 Protein |2 NLM | |
| 650 | 7 | |a ANKRD28 protein, human |2 NLM | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 700 | 1 | |a Shi, Yuhan |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yuexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Wenjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Haicheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of gene medicine |d 1997 |g 25(2023), 4 vom: 05. Apr., Seite e3478 |w (DE-627)NLM09753630X |x 1521-2254 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:4 |g day:05 |g month:04 |g pages:e3478 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jgm.3478 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 4 |b 05 |c 04 |h e3478 | ||